Viridian Therapeutics, Inc. (VRDN) Misses Q1 EPS by 60c

Viridian Therapeutics, Inc. (NASDAQ: VRDN) reported Q1 EPS of ($1.61), $0.60 worse than the analyst estimate of ($1.01). Revenue for the quarter came in at $100 thousand versus the consensus estimate of $131.38 thousand.

For earnings history and earnings-related data on Viridian Therapeutics, Inc. (VRDN) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Bernstein SocGen Reiterates Outperform Rating on Fervo Energy (FRVO)
• Deutsche Bank Starts DexCom (DXCM) at Buy